Skip To Main Content
Yuki Matsubara on Muck Rack

Yuki Matsubara

As seen in: Wiley Online Library, Taylor & Francis Online, Journal of Medical Case Reports, Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yuki

Contact Yuki, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Telisotuzumab adizutecan for metastatic colorectal cancer: a c-MET-targeted antibody–drug conjugate with a topoisomerase inhibitor payload

|
By Yuki Matsubara, Akihito Kawazoe
| Taylor & Francis Online
ABSTRACT Introduction Metastatic colorectal cancer (mCRC) remains a disease of significant unmet need, particularly for patients with refractory disease and limited targeted treatment. However, c-MET protein overexpression, which has been associated with poor prognosis, represents an emerging therapeutic target. Telisotuzumab adizutecan (Temab-A) is a novel antibody–drug conjugate designed to deliver a potent topoisomerase 1 inhibitor payload to c-MET-expressing tumor cells.
Open in Who Shared Issue with article?

Ramucirumab‐containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum‐based chemotherapy: A multicenter observational retrospective study (WJOG13420G)

|
By Yuki Matsubara, Toshiki Masuishi, Waki Hosoda, Hidekazu Hirano
| Wiley Online Library Verified
CI confidence interval DCR disease control rate ECOG PS Eastern Cooperative Oncology Group Performance Status FTD/TPI trifluridine/tipiracil GI-NEC gastrointestinal neuroendocrine carcinoma HR hazard ratio IPW inverse probability weighting NEC neuroendocrine carcinoma NEN neuroendocrine neoplasm ORR objective response rate OS overall survival PFS progression-free survival RAM ramucirumab VEGF vascular endothelial growth factor VEGFR-2 vascular endothelial growth factor receptor 2 WHO World...
Open in Who Shared Issue with article?
|
By Shinya Hanashima, Ryuji Ikeda, Yuki Matsubara, Tomokazu Yasuda, Hiroshi Tsuchikawa, J. Peter Slotte, Michio Murata
| Cell Press Verified
Open in Who Shared Issue with article?
See all 4 articles